Max Kemper

A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT

V. Budach, A. Abdollahi, I. Tinhofer, 2022, Cancers.

Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia

S. Löck, M. Krause, Karoline Leger, 2022, Acta oncologica.

Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.

V. Budach, A. Abdollahi, I. Tinhofer, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Analyses of molecular subtypes and their association to mechanisms ofradioresistance in patients with HPV-negative HNSCC treated bypostoperative radiochemotherapy.

V. Budach, A. Abdollahi, I. Tinhofer, 2022, Radiotherapy and Oncology.

The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: robust gene signature correlates with radiotherapy outcome in patients and xenografts.

I. Tinhofer, S. Pigorsch, F. Lohaus, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.